Physician profile
Katarzyna E Piotrowska
NPI 1205151453
$2,074.14
in general payments reported to CMS, 2019-2025
12 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $337 · 2021: $75.06 · 2022: $441 · 2023: $300 · 2024: $210 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.32 | 2019-2025 | |
| Amgen INC. | $369.90 | 2019-2022 | |
| Horizon Therapeutics Plc | $242.21 | 2019-2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $228.15 | 2019-2025 | Unithroid |
| Ibsa Pharma INC. | $225.18 | 2019-2023 | Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $141.29 | 2023-2025 | Yorvipath |
| Lilly USA, LLC | $119.33 | 2020-2024 | Retevmo |
| Alexion Pharmaceuticals, INC. | $102.08 | 2022 | |
| Shire North American Group INC | $59.36 | 2019 | |
| Eisai INC. | $54.59 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2019 | |
| Recordati_rare_diseases_inc. | $23.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katarzyna Piotrowska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.